Comprehensive Analysis Platform To Understand, Remedy and Eliminate ALS

What this study is about

CAPTURE ALS is a long-term data and biorepository platform that will facilitate future ALS research. CAPTURE ALS will provide the standardized systems and tools necessary to collect, store, and analyze vast amounts of multimodal information about ALS. These multimodal datasets and biosamples will be made available for use by researchers or industry across Canada and around the world in accordance with the CAPTURE ALS Data Sharing Policy to advance research on ALS.

Who can join (things the study team will check)

✅ You may be able to join if…

• Has ALS, classified as definite, probable, laboratory-supported probable, or possible ALS according to the revised El Escorial criteria or a related neurodegenerative disorder including ALS-FTD, PLS, PMA or asymptomatic individuals with a known ALS mutation (as previously confirmed during regular clinical care)
• Be of the age of majority in their province of residence/treatment
• Have the cognitive capacity to provide informed consent
• Have proficiency in English or French in order to understand study instructions and respond to questionnaires

✅ You may be able to join if…

• Be between the ages of 40-80 unless age matched to a patient (+/-3 years) who is already enrolled
• Be the age of majority in their province of residence/treatment
• Have the cognitive capacity to provide informed consent
• Have proficiency in English of French to understand study instructions and respond to questionnaires

🚫 You may not be able to join if…

• A history of a neurological disease, including Central Nervous System disease (e.g., stroke, head injury, epilepsy) or Peripheral Nervous System disease (neuropathy, myopathy)
• A history of psychiatric disease (e.g. depression, bipolar disease) that is clinically diagnosed and/or with the current use of psychiatric medications (e.g. antidepressants) for an indication of a psychiatric disease.
• Subjects ineligible for an MRI due to a pacemaker or other contraindication according to local MRI policies of the study centre.
• Significant claustrophobia that would prohibit an MRI (subjects will be required to lie in an MRI scanner for approximately one hour).

Where this trial is running

• University of Alberta, Edmonton, Alberta, Canada
• University of Toronto / Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
• McGill University / Montreal Neurological Institute and Hospital, Montreal, Quebec, Canada
• CHU de Quebec -Universite de Laval, Québec, Quebec, Canada

Who to contact

Claire Magnussen, PhD · 514-398-6188 · info@captureals.ca

It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT05204017.